- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00769327
Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML0408)
Front-line Treatment of Philadelphia Positive (Ph Pos), BCRABL Positive, Chronic Myeloid Leukemia (CML) With Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imotinib) A Phase II Exploratory Multicentric Centre.
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia.
Study Overview
Status
Conditions
Detailed Description
OBJECTIVES:
Primary
- To assess the complete cytogenetic response rate at 12 months in patients with Philadelphia chromosome- and BCR-ABL-positive early chronic phase chronic myelogenous leukemia treated with nilotinib and imatinib mesylate.
Secondary
- To assess the complete cytogenetic response rate at 6 and 24 months in these patients.
- To assess the major and complete molecular response rate at 6, 12, and 24 months in these patients.
- To assess the frequency and the types of BCR-ABL kinase domain mutations at 24 months during and for 3 years after study treatment.
- To assess the rate of failures and the time to failure at 12, 24, and 60 months in these patients.
- To assess compliance, toxicity, and adverse events in these patients.
- To understand the relationship between response, gene expression profile, biomarkers, and drug plasma concentrations in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral nilotinib twice daily in months 1-3, 7-9, 13-15, and 19-21 and oral imatinib mesylate once daily in months 4-6, 10-12, 16-18, and 22-24. Treatment continues for 24 months in the absence of disease progression or unacceptable toxicity. Patients may be eligible to continue oral nilotinib and oral imatinib mesylate for up to another 36 months if it is in the interest of the patient.
Blood samples and bone marrow biopsies are collected periodically for cytogenetic response by chromosome banding analysis and FISH analysis; real-time quantitative PCR mutational analysis and single nucleotide polymorphism analysis of BCR-ABL transcripts; and gene expression profiling and correlative biomarker studies.
After completion of study therapy, patients are followed every 6 months for 3 years and then every 12 months for 5 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Alessandria, Italy, I-15100
- Ospedale Civile Alessandria
-
Ascoli Piceno, Italy, 63100
- Dipartimento Area Medica P.O.
-
Avellino, Italy, 83100
- S.G. Moscati Hospital
-
Bari, Italy, 70010
- Unità Operativa Ematologia 1 - Università degli Studi di Bari
-
Bergamo, Italy, 24100
- Ospedali Riuniti di Bergamo
-
Bologna, Italy
- Ist.Ematologia e Oncologia Medica L.e A. Seragnoli
-
Cagliari, Italy
- ASL N.8 - Ospedale "A. Businco" - Struttura Complessa di Ematologia e CTMO
-
Catania, Italy
- Ctc U.O Di Ematologia Con Trapianto Di Midollo Osseo - Catania
-
Catania, Italy
- Unità di Oncoematologia Azienda Ospedaliera Garibaldi
-
Catanzaro, Italy
- Azienda Ospedaliera Pugliese Ciaccio - Presidio Ospedaliero A.Pugliese - Unità Operativa di Ematologia
-
Ferrara, Italy, 44100
- Sez.Ematologia e Dip. scienze Biomediche Arcispedale S. Anna
-
Firenze, Italy, 50011
- Azienda Ospedaliera di Firenze
-
Foggia, Italy
- Struttura Complessa di Ematologia Ospedali Riuniti Foggia - Azienda Ospedaliero-Universitaria
-
Genova, Italy
- Clinica Ematologica - DiMI - Università degli Studi di Genova
-
Genova, Italy
- Clinica Ematologica - Università degli Studi
-
Messina, Italy
- A.O. Universitaria Policlinico Martina di Messina
-
Messina, Italy
- Azienda Ospedaliera Ospedali Riuniti "Papardo Piemonte"
-
Modena, Italy
- Sez. di medicina Interna Oncologia ed Ematologia
-
Napoli, Italy
- Universtià degli Studi di Napoli "Federico II" - Facoltà di medicina e chirurgia
-
Novara, Italy
- S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro
-
Orbassano, Italy
- Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga
-
Palermo, Italy
- Ospedali Riuniti "Villa Sofia-Cervello"
-
Pescara, Italy, 65100
- U.O. Ematologia Clinica - Azienda USL di Pescara
-
Piacenza, Italy
- Unità Operativa Ematologia e Centro Trapianti - Dipartimento di Oncologia ed Ematologia - AUSL Ospedale di Piacenza
-
Reggio Calabria, Italy
- Dipartimento Emato-Oncologia A.O."Bianchi-Melacrino-Morelli"
-
Reggio Emilia, Italy
- Unità operativa complessa di Ematologia
-
Roma, Italy
- Complesso Ospedaliero S. Giovanni Addolorata
-
Roma, Italy
- A.O Umberto I
-
Roma, Italy
- Ospedale S.Eugenio
-
San Giovanni Rotondo, Italy
- Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza
-
Siena, Italy, 53100
- U.O. Ematologia, Azienda Ospedaliera Universitaria Senese
-
Terni, Italy
- Azienda Ospedaliera S. Maria di Terni
-
Torino, Italy
- SCDO Ematologia 2 AOU S.Giovanni Battista
-
Udine, Italy, 33100
- Policlinico Universitario Udine
-
Verona, Italy, 37134
- Policlinico G. B. Rossi - Borgo Roma
-
Vicenza, Italy, 36100
- Ospedale San Bortolo
-
-
Potenza
-
Rionero in Vulture, Potenza, Italy
- Centro Oncologico Basilicata
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Cytologically and cytogenetically confirmed chronic myelogenous leukemia meeting the following criteria:
- Early chronic phase disease (< 6 months from diagnosis)
- Philadelphia chromosome-positive disease
- BCR-ABL-positive
PATIENT CHARACTERISTICS:
- WHO performance status 0-1
- ALT and AST = 2.5 times upper limit of normal (ULN) (5.0 times ULN if considered due to leukemia)
- Alkaline phosphatase = 2.5 times ULN (unless considered due to leukemia)
- Serum bilirubin = 1.5 times ULN
- Serum creatinine = 1.5 times ULN
- Serum amylase = 1.5 times ULN
- Serum lipase = 1.5 times ULN
Normal serum levels of the following or correctable with supplements:
- Potassium
- Total calcium (corrected for serum albumin)
- Magnesium
- Phosphorus
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective barrier method contraception during study and for up to 3 months following completion of study treatment
No impaired cardiac function, including any of the following:
- LVEF < 45% by MUGA scan or echocardiogram
- Uncontrolled congestive heart failure
- Uncontrolled hypertension
- Uncontrolled angina pectoris
- Myocardial infarction within the past 12 months
No significant electric heart abnormalities, including any of the following:
- History or active ventricular or atrial tachyarrhythmias
- Congenital long QT syndrome and/or QTc > 450 msec on screening ECG
- No history of acute (within one year) or chronic pancreatitis
- No impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
- No acute or chronic liver or renal disease considered unrelated to leukemia
- No known diagnosis of HIV infection
- No other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes, active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol
- No other primary malignancy that is currently clinically significant or requires active intervention
PRIOR CONCURRENT THERAPY:
- More than 2 weeks since prior major surgery and recovered
- More than 30 days since prior imatinib mesylate, with a washout period of ≥ 7 days
- More than 4 weeks since prior investigational drug
- No prior hematopoietic stem cell transplantation
- No concurrent therapeutic coumarin derivates (i.e., warfarin, acenocoumarol, phenprocoumon)
- No concurrent medications that would prolong the QT interval
- No concurrent chemotherapy, investigational agents, radiotherapy, or biologic therapy
- Prior treatment with hydroxyurea or anagrelide allowed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Complete cytogenetic response rate
Time Frame: At 12 months from study entry
|
At 12 months from study entry
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Complete cytogenetic response
Time Frame: At at 6 and 24 months from study entry
|
At at 6 and 24 months from study entry
|
Major and complete molecular response rate
Time Frame: At at 6, 12 and 24 months from study entry
|
At at 6, 12 and 24 months from study entry
|
Development of BCR-ABL kinase domain mutations (number, timing, and type)
Time Frame: At at 24 months during and for 3 years after study treatment
|
At at 24 months during and for 3 years after study treatment
|
Rate of failures and the time to failure
Time Frame: At 12, 24, and 60 months from study entry
|
At 12, 24, and 60 months from study entry
|
Safety and tolerability
Time Frame: At 24 months from study entry
|
At 24 months from study entry
|
Frequency and type of adverse events (AE) and severe AE
Time Frame: At 24 months from study entry
|
At 24 months from study entry
|
Relationship between response, the gene expression profile, the biomarkers of leukemic cells, and plasma concentrations of nilotinib and imatinib mesylate
Time Frame: At 24 months from study entry
|
At 24 months from study entry
|
Collaborators and Investigators
Investigators
- Principal Investigator: Michele Baccarani, MD, Gruppo Italiano Malattie EMatologiche dell'Adulto
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Leukemia, Myeloid
- Leukemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Chronic-Phase
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Imatinib Mesylate
Other Study ID Numbers
- CML0408
- GIMEMA-CML0408
- EUDRACT-2008-004384-19
- EU-20881
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia
-
Massachusetts General HospitalCelgene CorporationTerminatedAcute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic LeukemiaUnited States
-
Institute of Hematology & Blood Diseases HospitalBejing Institute for Stem Cell and Regenerative Medicine; Institute for Stem...RecruitingRefractory Leukemia | Relapsed Leukemia | Acute Myeloid Leukemia, ChildhoodChina
-
Stanford UniversityTerminatedLeukemia | Leukemia, Lymphocytic, Acute | Leukemia Acute Promyelocytic Leukemia (APL) | Leukemia Acute Lymphoid Leukemia (ALL) | Leukemia Chronic Myelogenous Leukemia (CML) | Leukemia Acute Myeloid Leukemia (AML) | Leukemia Chronic Lymphocytic Leukemia (CLL)United States
-
Betta Pharmaceuticals Co., Ltd.Not yet recruitingAcute Myeloid Leukemia LeukemiaChina
-
Center for International Blood and Marrow Transplant...National Marrow Donor Program; St. Baldrick's FoundationActive, not recruitingAcute Myelogenous LeukemiaUnited States
-
Massachusetts General HospitalCompleted
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
-
Hybrigenics CorporationUnknownAcute Myelogenous LeukemiaUnited States, France
-
National Cancer Institute (NCI)TerminatedAdult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditionsUnited States
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
Clinical Trials on polymorphism analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedMultiple Myeloma and Plasma Cell Neoplasm
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Southwest Oncology GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology GroupCompleted
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedGastrointestinal Stromal TumorUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Southwest Oncology GroupNational Cancer Institute (NCI)Completed
-
Doctors with Africa - CUAMMCatholic University of the Sacred Heart; University of Bari "Aldo Moro", Bari... and other collaboratorsNot yet recruitingMalaria | Malaria in Pregnancy
-
Cancer Research UKUnknown
-
Cancer Research UKUnknown